Literature DB >> 32166662

Selection for Anti-transferrin Receptor Bispecific T-cell Engager in Different Molecular Formats.

Ming-Peng Fu1, Zi-Long Guo1, Hong-Ling Tang1, Hui-Fen Zhu1, Guan-Xin Shen1, Yong He2, Ping Lei3.   

Abstract

Selecting an ideal molecular format from diverse structures is a major challenge in developing a bispecific antibody (BsAb). To choose an ideal format of anti-CD3 × anti-transferrin receptor (TfR) bispecific antibodies for clinical application, we constructed TfR bispecific T-cell engager (BiTE) in two extensively applied formats, including single-chain tandem single-chain variable fragments (scFvs) and double-chain diabodies, and evaluated their functional characterizations in vitro. Results demonstrated that TfR-BiTE in both formats directed potent killing of TfR+ HepG2 cells. However, compared to two-chain diabodies, scFvs were more efficient in antigen binding and TfR+ target killing. Furthermore, different domain orders in scFvs would also be evaluated because single-TfR-CD3-His was preferable to single-CD3-TfR-His in immunotherapeutic strategies. Thus, the single-chain tandem TfR-CD3 format was favored for further investigation in cancer therapy.

Entities:  

Keywords:  CD3; bispecific antibody; diabody; single-chain tandem single-chain variable fragments; transferrin receptor

Mesh:

Substances:

Year:  2020        PMID: 32166662     DOI: 10.1007/s11596-020-2143-y

Source DB:  PubMed          Journal:  Curr Med Sci        ISSN: 2523-899X


  28 in total

1.  Two heads are better than one.

Authors:  Sherie L Morrison
Journal:  Nat Biotechnol       Date:  2007-11       Impact factor: 54.908

2.  Bispecific antibodies rise again.

Authors:  Ken Garber
Journal:  Nat Rev Drug Discov       Date:  2014-11       Impact factor: 84.694

Review 3.  Alternative molecular formats and therapeutic applications for bispecific antibodies.

Authors:  Christoph Spiess; Qianting Zhai; Paul J Carter
Journal:  Mol Immunol       Date:  2015-01-27       Impact factor: 4.407

4.  A diabody that dissociates to monomer forms at low concentration: effects on binding activity and tumor targeting.

Authors:  Bao-Cheng Huang; Linda J Foote; Trish K Lankford; Sandra M Davern; Cathy K McKeown; Stephen J Kennel
Journal:  Biochem Biophys Res Commun       Date:  2005-02-25       Impact factor: 3.575

Review 5.  T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

Authors:  Z Wu; N V Cheung
Journal:  Pharmacol Ther       Date:  2017-08-20       Impact factor: 12.310

Review 6.  BiTEs: bispecific antibody constructs with unique anti-tumor activity.

Authors:  Evelyn Wolf; Robert Hofmeister; Peter Kufer; Bernd Schlereth; Patrick A Baeuerle
Journal:  Drug Discov Today       Date:  2005-09-15       Impact factor: 7.851

Review 7.  Bispecific T-cell engaging antibodies for cancer therapy.

Authors:  Patrick A Baeuerle; Carsten Reinhardt
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701

Review 8.  Bispecific antibodies for cancer therapy: A review.

Authors:  Anuradha Krishnamurthy; Antonio Jimeno
Journal:  Pharmacol Ther       Date:  2017-12-18       Impact factor: 12.310

Review 9.  Novel immunotherapies in lymphoid malignancies.

Authors:  Connie Lee Batlevi; Eri Matsuki; Renier J Brentjens; Anas Younes
Journal:  Nat Rev Clin Oncol       Date:  2015-11-03       Impact factor: 66.675

10.  A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity.

Authors:  M Mack; G Riethmüller; P Kufer
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

View more
  2 in total

Review 1.  Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors.

Authors:  Jim Middelburg; Kristel Kemper; Patrick Engelberts; Aran F Labrijn; Janine Schuurman; Thorbald van Hall
Journal:  Cancers (Basel)       Date:  2021-01-14       Impact factor: 6.639

2.  The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies.

Authors:  Zilong Guo; Yirui Zhang; Mingpeng Fu; Liang Zhao; Zhen Wang; Zhuoshuo Xu; Huifen Zhu; Xiaoli Lan; Guanxin Shen; Yong He; Ping Lei
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.